Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.02 |
---|---|
High | 5.19 |
Low | 4.80 |
Bid | 5.04 |
Offer | 5.05 |
Previous close | 4.91 |
Average volume | 830.35k |
---|---|
Shares outstanding | 61.17m |
Free float | 53.88m |
P/E (TTM) | -- |
Market cap | 300.36m USD |
EPS (TTM) | -5.58 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 20:33 GMT.
More ▼
- Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
- Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
- Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
- Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
- Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
- Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
More ▼